Welcome to our dedicated page for Cigna Group SEC filings (Ticker: CI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cigna Group SEC filings document financial results, governance actions and material events for a global health company operating through Cigna Healthcare, Evernorth Health Services and related subsidiaries. Form 8-K reports cover results of operations and financial condition, Regulation FD outlook disclosures, board and committee changes, leadership succession matters and shareholder meeting results.
Proxy materials describe director elections, executive compensation, shareholder voting items, board composition and governance practices. The filing record also includes exhibits for earnings releases and Inline XBRL cover data, tying formal disclosures to the company’s pharmacy benefit services, specialty and care services, health benefits operations, compliance oversight and public-company capital structure.
The Cigna Group reported initial equity holdings for officer Bryan Holgerson. He holds 6,957 shares of common stock directly and 735.9274 shares indirectly through The Cigna Group’s 401(k) Plan. In addition, he has 941.8085 phantom stock units, each economically equivalent to one common share but settled in cash under the Executive Deferred Compensation Plan. Holgerson also holds several employee stock option grants covering 10 separate blocks of common stock at exercise prices between $183.4405 and $336.4750, with vesting in three annual installments and expirations between 2028 and 2036.
Cigna Group officer Adam Kautzner filed an initial ownership report on Form 3. He holds 13,532.5100 shares of Cigna common stock directly. He also holds several employee stock options to buy Cigna common stock, with exercise prices between $183.4405 and $336.4750 and expirations from 2029 through 2036, vesting in three equal annual installments as described.
Cigna Group officer Jason D. Sadler filed an initial ownership report showing direct holdings of 34,705 shares of common stock. He also holds several employee stock options to acquire additional common shares at exercise prices between $287.5475 and $336.4750, with expirations from 2033 to 2036. Footnotes state these options vest in three equal annual installments beginning on March 1 of 2024, 2025, 2026, and 2027, as applicable.
Cigna Group reported the initial holdings of officer Sanford Paul A in its common stock. The report lists 4,073 shares of Common Stock, $.01 par value, held directly. No specific buy, sell, or derivative transactions are disclosed; the entry records existing ownership.
Cigna Group officer Matthew Perlberg reported his initial beneficial ownership of company equity. He directly holds 9,345 shares of common stock. He also holds several employee stock options to acquire additional common shares, with exercise prices between $227.0200 and $336.4750 and expiration dates ranging from 2032 to 2036. Footnotes state these options vest in three equal annual installments beginning on various March 1 dates from 2023 through 2027.
Cigna Group Chief Accounting Officer Jamie G. Kates exercised employee stock options for 899 shares of common stock at $152.8947 per share and, on the same date, sold 899 shares in an open-market transaction at $298.612 per share. Following these transactions, Kates directly holds 2,368 Cigna common shares. The exercised option was originally granted on February 28, 2018 and vested in three equal annual installments beginning February 28, 2019.
Cigna Group executive Durga Prasad Koka, EVP and Global CIO, reported a routine tax-related share disposition. On the vesting of restricted shares, 729 common shares were withheld to cover tax obligations at an indicated value of $275.53 per share. After this withholding, Koka directly holds 6,552 Cigna common shares. This was not an open-market sale, but an automatic mechanism tied to equity compensation.
Kurian George reported acquisition or exercise transactions in this Form 4 filing.
The Cigna Group director George Kurian received 108.1471 Phantom Stock Units on May 29, 2026 as a grant under the company’s director deferred compensation plan. These units reflect a voluntary deferral of his cash retainer at $277.40 per unit and are economically equivalent to common shares but will be settled in cash. Following this award and related dividend reinvestments, he holds a total of 1,922.4494 phantom stock units linked to Cigna common stock.
The Cigna Group’s Chairman and CEO David Cordani exercised employee stock options and sold shares in a pre-planned series of transactions. On May 12–13, 2026, he exercised options covering 212,543 shares of common stock at exercise prices of $149.135 and $197.35 per share, converting them into common shares.
Over the same period, he conducted open-market sales totaling 201,878 shares of common stock at weighted average prices generally between about $286 and $299 per share, according to price ranges in the filing. These sales were made under a Rule 10b5-1 trading plan adopted on February 6, 2026, meaning they were pre-arranged rather than opportunistic.
After these transactions, Cordani directly owned 57,766 shares of Cigna Group common stock. The filing also lists additional indirect holdings, including shares held through a 401(k) plan, a trust, and a GRAT, which are separate from his direct position.